Worth reading
52Recurring
Scored from 5 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-20.4
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedJapanese GAAPNet Sales916Millions of yenYear on year -20.4%Progress 12.7%
Operating profit-98Millions of yen
Ordinary income-93Millions of yen
Net income attributable to owners of the parent-95Millions of yen
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share△¥1.89
Financial position at period-end
Total assets11,325Millions of yen
of which net assets 8,264 Millions of yenEquity ratio 73.0%vs. prior year-end +3.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenuePharmaceuticals Business 858 Millions of yen (YoY -13.2%), Infection-Control Business 56 Millions of yen (YoY -64.6%), Other businesses 1 Millions of yen
Segment profitPharmaceuticals Business 160 Millions of yen (YoY -49.0%), Infection-Control Business -41 Millions of yen, Other businesses -5 Millions of yen
Regional salesBusiness Pharmaceuticals Business / Region Domestic / Current fiscal year 659 Millions of yen / Prior-year period 903 Millions of yen / yoy_pct -27, Business Pharmaceuticals Business / Region Overseas expansion / Current fiscal year 198 Millions of yen / Prior-year period 86 Millions of yen / yoy_pct 130.6, Business Infection-Control Business / Region Japan: OTC / Current fiscal year 10 Millions of yen / Prior-year period 96 Millions of yen / yoy_pct Not disclosed, Business Infection-Control Business / Region Japan: professional use / Current fiscal year 39 Millions of yen / Prior-year period 50 Millions of yen / yoy_pct Not disclosed, Business Infection-Control Business / Region Overseas expansion / Current fiscal year 6 Millions of yen / Prior-year period 13 Millions of yen / yoy_pct Not disclosed
Outlook and shareholder returns
Full-year earnings forecast
Net Sales7,200 Millions of yen (YoY +12.5%)
Operating profit500 Millions of yen (YoY +8.9%)
Ordinary income520 Millions of yen (YoY +7.7%)
Net income550 Millions of yen (YoY -40.4%)
Annual Dividend Forecast¥3.3 → ¥3.5
Factors Behind Changes in Business Performance
In the Pharmaceuticals business, revenue remained sluggish due to supply shortages of Seirogan, the resumption of supplies of competing products and weaker inbound demand. In the Infection Control business, revenue declined due to a pullback from the increase in demand caused by the influenza outbreak in the same period of the previous year. Gross profit declined due to higher costs associated with strengthening the supply system for the Pharmaceuticals business, while selling, general and administrative expenses decreased, mainly due to lower advertising and promotional expenses in the Infection Control business.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name No applicable matters.
Breakdown of extraordinary income (loss)Current fiscal year Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets 0 Millions of yen / Prior-year period Extraordinary income Gain on sale of investment securities 347 Millions of yen, Compensation received 10 Millions of yen / Extraordinary loss Not disclosed
Depreciation and amortization73 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable No / Subject person No participants
Issued Shares at Period-End50,636,900 Shares
Treasury Shares at Period-End385,713 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | 916 Millions of yen (YoY -20.4%) |
| Operating profit | -98 Millions of yen |
| Ordinary income | -93 Millions of yen |
| Profit attributable to owners of the parent | -95 Millions of yen |
| Net income per share | △¥1.89 |
| Equity ratio | End of the current fiscal period 73 / End of previous period 69.4 |
| Total assets | 11,325 Millions of yen |
| Net assets | 8,264 Millions of yen |
| Full-year earnings forecast | Net Sales 7,200 Millions of yen (YoY +12.5%) / Operating profit 500 Millions of yen (YoY +8.9%) / Ordinary income 520 Millions of yen (YoY +7.7%) / Net income 550 Millions of yen (YoY -40.4%) |
| Annual Dividend Forecast | ¥3.3 → ¥3.5 |
| Segment revenue | Pharmaceuticals Business 858 Millions of yen (YoY -13.2%), Infection-Control Business 56 Millions of yen (YoY -64.6%), Other businesses 1 Millions of yen |
| Segment profit | Pharmaceuticals Business 160 Millions of yen (YoY -49.0%), Infection-Control Business -41 Millions of yen, Other businesses -5 Millions of yen |
| Regional sales | Business Pharmaceuticals Business / Region Domestic / Current fiscal year 659 Millions of yen / Prior-year period 903 Millions of yen / yoy_pct -27, Business Pharmaceuticals Business / Region Overseas expansion / Current fiscal year 198 Millions of yen / Prior-year period 86 Millions of yen / yoy_pct 130.6, Business Infection-Control Business / Region Japan: OTC / Current fiscal year 10 Millions of yen / Prior-year period 96 Millions of yen / yoy_pct Not disclosed, Business Infection-Control Business / Region Japan: professional use / Current fiscal year 39 Millions of yen / Prior-year period 50 Millions of yen / yoy_pct Not disclosed, Business Infection-Control Business / Region Overseas expansion / Current fiscal year 6 Millions of yen / Prior-year period 13 Millions of yen / yoy_pct Not disclosed |
| Depreciation and amortization | 73 Millions of yen |
| Breakdown of extraordinary income (loss) | Current fiscal year Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets 0 Millions of yen / Prior-year period Extraordinary income Gain on sale of investment securities 347 Millions of yen, Compensation received 10 Millions of yen / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person No participants |
| Issued Shares at Period-End | 50,636,900 Shares |
| Treasury Shares at Period-End | 385,713 Shares |
| Factors Behind Changes in Business Performance | In the Pharmaceuticals business, revenue remained sluggish due to supply shortages of Seirogan, the resumption of supplies of competing products and weaker inbound demand. In the Infection Control business, revenue declined due to a pullback from the increase in demand caused by the influenza outbreak in the same period of the previous year. Gross profit declined due to higher costs associated with strengthening the supply system for the Pharmaceuticals business, while selling, general and administrative expenses decreased, mainly due to lower advertising and promotional expenses in the Infection Control business. |
Items this document does not state (11)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Pharmaceuticals business, revenue remained sluggish due to supply shortages of Seirogan, the resumption of supplies of competing products and weaker inbound demand. In the Infection Control business, revenue declined due to a pullback from the increase in demand caused by the influenza outbreak in the same period of the previous year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.